Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.63 |
| ▸ | CSNK1D | P48730 | 13/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | SCN4A | P35499 | 1/20 | 0.55 |
| ▸ | ACP1 | P24666 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10189473 | 0.87 | CSNK1D (0.49) | DYRK1ACSNK1DACP1CYP2D6MAPK14 | |
| SCHEMBL5683714 | 0.83 | DYRK1A (0.68) | DYRK1ACSNK1DEPHX2SCN4AACP1 | |
| SCHEMBL19840307 | 0.82 | CSNK1D (0.44) | DYRK1ACSNK1DACP1MAPK14 | |
| SCHEMBL28878445 | 0.81 | DYRK1A (0.64) | DYRK1ACSNK1DEPHX2SCN4AACP1 | |
| SCHEMBL29974674 | 0.81 | DYRK1A (0.64) | DYRK1ACSNK1DEPHX2SCN4AACP1 | |
| SCHEMBL2116732 | 0.80 | KDM4E (0.64) | DYRK1ACSNK1DEPHX2SCN4AACP1 | |
| SCHEMBL8430853 | 0.80 | DYRK1A (0.68) | DYRK1ACSNK1DEPHX2SCN4AACP1 | |
| SCHEMBL16884504 | 0.79 | DYRK1A (0.65) | DYRK1ACSNK1DSCN4AACP1MAPK14 | |
| SCHEMBL18058957 | 0.78 | NPC1 (0.59) | DYRK1AACP1MAPK14 | |
| SCHEMBL4499710 | 0.77 | MAPK14 (0.47) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | DYRK1A 3766/4885CSNK1D 4320/4885EPHX2 1875/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | DYRK1A 1462/4885CSNK1D 2424/4885EPHX2 2895/4885 |
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | M6PR, ASGR1, IGF2R | DYRK1A 2551/4885CSNK1D 4401/4885EPHX2 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.